West Pharmaceutical Services, Inc.(WST) Stock Research - Grey Stern Research
Loading...

West Pharmaceutical Services, Inc. (WST) Stock Analysis

$355.64 (0.43%)

WST Financial Performance


Use the table below to view West Pharmaceutical Services, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2023

Metric Value Ranking among Peers
Price $354.11 -
52 Week Low $310.42 -
52 Week High $415.73 -
Market Cap $25.8 Billion 3/12
Gross Margin 38% 9/12
Profit Margin 19% 2/12
EBITDA margin 29% 3/12
Q4 - 2023 Revenue $732.0 Million 6/12
Q4 - 2023 Earnings $137.0 Million 4/12
Q4 - 2023 Free Cash Flow $130.4 Million 4/12
Trailing 4 Quarters Revenue $2.9 Billion 6/12
Trailing 4 Quarters Earnings $593.4 Million 4/12
Quarterly Earnings Growth 33% 3/12
Annual Earnings Growth 28% 4/12
Quarterly Revenue Growth 3% 6/12
Annual Revenue Growth 7% 1/12
Cash On Hand $853.9 Million 4/12
Short Term Debt $151.7 Million 3/12
Long Term Debt $157.3 Million 12/12

West Pharmaceutical Services, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare West Pharmaceutical Services, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 43.47 5/12
PS 8.74 2/12
PB 8.95 1/12
PC 30.21 4/12
Liabilities to Equity 0.33 11/12
ROA 0.15 1/12
ROE 0.21 2/12
Current Ratio 4.04 1/12
Quick Ratio 0.90 1/12
Long Term Debt to Equity 0.05 11/12
Debt to Equity 0.11 11/12
Burn Rate -9.20 11/12
Cash to Cap 0.03 9/12
CCR 0.95 3/12
EV to EBITDA 117.99 5/12
EV to Revenue 8.56 2/12

Company Details

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

CEO: Mr. Eric Green

Website: https://www.westpharma.com

Address: 530 HERMAN O WEST DR Exton, PENNSYLVANIA

Exchange: New York Stock Exchange

Industry: Medical Instruments & Supplies

West Pharmaceutical Services, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to West Pharmaceutical Services, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Becton, Dickinson and Company BDX $68.3 Billion
Hologic, Inc. HOLX $17.5 Billion
Baxter International Inc. BAX $18.0 Billion
ResMed Inc. RMD $32.1 Billion
The Cooper Companies, Inc. COO $19.3 Billion
Haemonetics Corporation HAE $4.9 Billion
Teleflex Incorporated TFX $10.3 Billion
Merit Medical Systems, Inc. MMSI $4.8 Billion
ICU Medical, Inc. ICUI $2.5 Billion
Repligen Corporation RGEN $9.6 Billion
Embecta Corp. EMBC $833.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
WST Income Statements
Quarter Year Revenue Earnings
Q4 2023 $ 732.0 Million $137.0 Million
Q3 2023 $ 747.4 Million $161.3 Million
Q2 2023 $ 753.8 Million $155.1 Million
Q1 2023 $ 716.6 Million $140.0 Million
Q4 2022 $ 708.7 Million $103.0 Million
Q3 2022 $ 686.9 Million $120.6 Million
Q2 2022 $ 771.3 Million $188.5 Million
Q1 2022 $ 720.0 Million $173.8 Million

View All

WST Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2023 $853.9 Million $3.8 Billion $309.0 Million $2.9 Billion
Q3 2023 $898.6 Million $3.8 Billion $306.8 Million $2.9 Billion
Q2 2023 $796.3 Million $3.7 Billion $311.3 Million $2.7 Billion
Q1 2023 $886.3 Million $3.7 Billion $314.4 Million $2.8 Billion
Q4 2022 $894.3 Million $3.6 Billion $317.9 Million $2.7 Billion
Q3 2022 $729.0 Million $3.3 Billion $299.9 Million $2.5 Billion
Q2 2022 $718.5 Million $3.4 Billion $332.5 Million $2.4 Billion
Q1 2022 $667.7 Million $3.3 Billion $331.2 Million $2.3 Billion

View All

WST Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2023 $130.4 Million -$108.7 Million -$44.7 Million
Q3 2023 $230.1 Million $0 $230.1 Million
Q2 2023 $93.8 Million -$75.4 Million -$90.0 Million
Q1 2023 $56.0 Million -$82.1 Million -$8.0 Million
Q4 2022 $135.9 Million -$94.9 Million $165.3 Million
Q3 2022 $111.1 Million -$57.8 Million $10.5 Million
Q2 2022 $107.0 Million -$66.1 Million $50.8 Million
Q1 2022 $85.4 Million -$65.8 Million -$94.9 Million

View All